NICE Technology Appraisals in the NHS in England - to March 2014, Experimental statistics, Innovation scorecard

The Innovation Health and Wealth paper published by the Department of Health in December 2011, set out plans to support development and adoption of innovation in the NHS.  An action in this paper is to drive compliance with technology appraisals by the publication of information by the Health and Social Care Information Centre showing variation at a local level.

The National Institute for Health and Care Excellence (NICE) technology appraisal process assesses the clinical and cost effectiveness of new and existing medicines and treatments, and provides guidance on their use by the NHS.

There is no central collection of data which can directly support the assessment of compliance, nor is data on the number of patients treated available.Therefore this is an experimental publication, which makes use of data currently available from a range of sources. The HSCIC and NHS England welcome comments and suggestions from users to support future development of appropriate datasets and reporting.

The data is presented in the form of two interactive spreadsheets which use macros to allow users to identify the organisations and interventions they wish to explore. The data is also presented in tables and charts.  An accompanying report describes the data, the sources and its limitations. Please note that the interactive spreadsheets should  be viewed in conjunction with this report, and the caveats to interpretation should be noted.

There are a series of publications since January 2013, each includes developments and additional technologies. In this sixth publication, local data is shown for April 2013 to March 2014. Additional developments in this publication include:
The number of medicines and medical technologies included in parts 2 and 3 is increased.

Part 5 now shows the utilisation over time for a wider range of medicines at both National and Area Team level. This is presented as both charts and tables, showing relative use by healthcare sector.

Map based visualisation is also provided in an accompanying spreadsheet.

Three of the estimates included in Part 1 have been updated with 2013/14 data, and presented in an additional report. It is intended that the number of estimates included in future versions of the Innovation Scorecard will be expanded substantially.
It is not appropriate to draw conclusions from comparison of the data in each scorecard publication. Additional medicines and additional hospitals trusts have been included in each publication. Many factors may be responsible for any apparent variation including differences in populations served, services provided and changes in clinical practice.

NHS England have released additional data and analysis, at the link provided below. Note that some of the time periods, definitions and medicines used by NHS England differ to what is published here.